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N-glycolylneuraminic acid (NeuGc) is a sialic acid molecule usually found in mammalian
cells as terminal constituents of different membrane glycoconjugates such as
gangliosides. The NeuGcGM3 ganglioside has been described as a tumor antigen for
non-small cell lung cancer (NSCLC) in humans. Racotumomab is an anti-NeuGc-containing
gangliosides anti-idiotype monoclonal antibody (mAb) (formerly known as 1E10) that has
received attention as a potential active immunotherapy for advanced lung cancer in
clinical trials. In this work, we have examined the antitumor activity of racotumomab
in combination or not with chemotherapy, using the 3LL Lewis lung carcinoma as
a preclinical model of NSCLC in C57BL/6 mice. Vaccination with biweekly doses of
racotumomab at 50–200μg/dose formulated in aluminum hydroxide (racotumomab-alum
vaccine) demonstrated a significant antitumor effect against the progression of lung
tumor nodules. Racotumomab-alum vaccination exerted a comparable effect on lung
disease to that of pemetrexed-based chemotherapy (100mg/kg weekly). Interestingly,
chemo-immunotherapy was highly effective against lung nodules and well-tolerated,
although no significant synergistic effect was observed as compared to each treatment
alone in the present model. We also obtained evidence on the role of the exogenous
incorporation of NeuGc in the metastatic potential of 3LL cells. Our preclinical data provide
support for the combination of chemotherapy with the anti-idiotype mAb racotumomab,
and also reinforce the biological significance of NeuGc in lung cancer.
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INTRODUCTION
N-glycolylneuraminic acid (NeuGc) is a sialic acid molecule
usually found in mammalian cells as terminal constituents of dif-
ferent membrane glycoconjugates such as the GM3 ganglioside
(NeuGcGM3). Gangliosides are a broad family of glycosphin-
golipids found on the outer cell membrane, involved in cell
communication, regulation of the immune response, and cancer
progression (Patra, 2008; Lopez and Schnaar, 2009). NeuGcGM3
has been described as a tumor antigen for non-small cell lung
cancer (NSCLC) in humans (van Cruijsen et al., 2009; Blanco
et al., 2012). The significance of NeuGc overexpression in human
cancer is still under investigation. Considering that anti-NeuGc
antibodies can be detected in several cancer patients, it was
hypothesized that antibody-mediated inflammation could facil-
itate tumor progression (Varki, 2010). However, it is widely
accepted that high titers of these antibodies can induce tumor
cell death (Roque Navarro et al., 2008; Varki, 2010; Hernandez
et al., 2011). In addition, experimental data indicated that
growth-stimulating features of NeuGc on tumor cells can be
explained by immune system down-modulation (De Leon et al.,
2008).
Racotumomab is an anti-NeuGc-containing gangliosides anti-
idiotype monoclonal antibody (mAb), formerly known as 1E10,
that has received attention as a potential active immunotherapy
for advanced lung cancer in clinical trials (Neninger et al., 2007;
Alfonso et al., 2008). As an anti-idiotype antibody, racotumomab
is themirror imageof theP3mAb idiotypewhich specifically reacts
against NeuGc antigens on cell surface (Vazquez et al., 1998).
Previously, we evaluated the antitumor activity of racotu-
momab in syngeneic mouse tumor models. Vaccination with
several biweekly intraperitoneal doses of racotumomab coupled
to keyhole limpet hemocyanin in Freund’s adjuvant, significantly
inhibited the formation of spontaneous lung metastases by F3II
mammary carcinoma cells (Vazquez et al., 2000). Administration
of low-dose cyclophosphamide together with subcutaneous
immunization with aluminum hydroxide-precipitated racotu-
momab (racotumomab-alum vaccine) significantly reduced F3II
primary tumor growth. The antitumor response was compa-
rable to that obtained with standard high-dose chemother-
apy in such breast cancer model, but without overt signs of
toxicity. Interestingly, combinatory chemo-immunotherapy pro-
moted CD8+ lymphocyte tumor infiltration and increased tumor
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apoptosis (Fuentes et al., 2010). In addition, intravenous admin-
istration of uncoupled racotumomab, as a biological response
modifier, dramatically inhibited metastatic lung colonization by
B16 melanoma cells (Vazquez et al., 2000).
In the present work, we have examined the antitumor activity
of racotumomab-alum in combination or not with pemetrexed-
or taxane-based chemotherapy, using the 3LL Lewis lung car-
cinoma in C57BL/6 mice as a preclinical model of NSCLC. It
is a validated model for the NeuGcGM3 ganglioside, showing
an increased expression of such specific antigen in disseminated
nodules with respect to the primary tumor or in vitro cultured
cells (Labrada et al., 2010). In this regard, we also obtained evi-
dence on the role of the exogenous incorporation of NeuGc in the
metastatic potential of 3LL cells.
MATERIALS AND METHODS
RACOTUMOMAB-ALUM VACCINE
Racotumomab was produced by the Center of Molecular
Immunology (La Habana, Cuba). The mAb was purified from
mouse ascites by good manufacturing practices, as previously
described (Alfonso et al., 2002). Briefly, purification was per-
formed by DEAE-exchange chromatography followed by affin-
ity chromatography and size exclusion chromatography using a
Sephadex G-25 column. The vaccine preparation was produced
by mixing aluminum hydroxide as adjuvant with purified racotu-
momab at a final concentration of 1mg/ml. Some experiments
were carried out using a bioreactor-obtained mAb, as recently
described by Machado et al. (2011).
TUMOR CELLS AND CULTURE CONDITIONS
We used the 3LL Lewis lung carcinoma, clone D122, a
low immunogenic and high-metastatic cell line in syngeneic
C57BL/6 mice (Eisenbach et al., 1984). Additionally, the X63
murine myeloma cell line, expressing high levels of NeuGcGM3
in its membranes, was employed. Tumor cells were main-
tained in Dulbecco’s Modified Eagle Media (DMEM) culture
medium (Gibco BRL, Carlsbad, CA, USA) containing 10% heat-
inactivated fetal bovine serum. Cells were subcultured twice
a week using trypsin-EDTA, and cell viability was assessed
using the trypan blue exclusion technique. The concentration of
chemotherapy drug causing 50% growth inhibition (IC50) was
determined by the MTT colorimetric assay.
ANIMALS
Pathogen-free C57BL/6 mice (approximately 10 weeks-old, with
an average weight of 25 g) were obtained from the Animal Care
Division of UNLP (La Plata, Argentina). Up to 5–6 mice per
cage were kept with water and food ad libitum in the animal
house facility at Quilmes National University. Pooled sera from
experimental or control groups were obtained, and frozen at
−20◦C in aliquots for further analysis. Experimental protocols
were approved by the Animal Review Board and maintenance of
animals was conducted under accepted international standards.
Ex vivo NeuGc PREINCUBATION
Tumor cells were harvested with trypsin-EDTA solution
and resuspended in serum-free DMEM containing NeuGc
(Sigma-Aldrich, St. Louis, MO, USA) at a final concentration of
100μg/ml. After an incubation of 1 h at 37◦C, 3LL cells were
extensively washed and resuspended in fresh culture medium.
NeuGcGM3 DETECTION BY FLOW CYTOMETRIC ASSAY
We used the specific anti-NeuGcGM3 mouse IgG1mAb 14F7
(Carr et al., 2000), produced by the Center of Molecular
Immunology. Tumor cells were harvested with trypsin-EDTA
solution, resuspended in serum-free DMEM, and 0.5–1×106 cells
per sample were incubated with 2μg of 14F7, isotype control,
or mouse sera (dilution 1:50) for 30min at room temperature.
Then, tumor cells were washed with phosphate buffered saline
and incubated with R-phycoerythrin-conjugated goat anti-mouse
immunoglobulins (DakoCytomation, Carpinteria, CA, USA) for
30min at 4◦C. A total of 5 × 104 events were analyzed per tube
with a FACScan flow cytometer (Becton Dickinson, San Jose, CA,
USA), using the WinMDI 2.9 software.
PRIMARY TUMOR GROWTH AND SPONTANEOUS METASTASES
At day 0, groups of at least six mice were inoculated subcuta-
neously in the right flank with 3LL cells (4–5×105 viable cells
per mouse in 0.2ml of DMEM). Primary tumor development
was monitored by palpation. The largest perpendicular tumor
diameters were measured with a caliper thrice a week, and tumor
volumes were calculated using the formula π/6 × length ×
width2. Animals were sacrificed by cervical dislocation at day 50
or when subcutaneous tumor volume exceeded 3,000mm3. Lungs
were fixed in Bouin’s solution and surface lung nodules were
counted under a dissecting microscope, as described elsewhere
(Alonso et al., 1996). Four doses of 50μg of racotumomab-alum
vaccine were administered s.c. in the interescapular area at 14-
day intervals, beginning the day tumor cell inoculation (days 0,
14, 28, and 42). Control animals received only the saline vehi-
cle. When tumors became palpable at day 10–12, mice received
3 weekly i.p. doses of pemetrexed (100mg/kg) or docetaxel
(20mg/kg).
EXPERIMENTAL LUNG METASTASES
At day 0, groups of at least eight mice were injected into the
lateral tail vein with control or NeuGc-preincubated 3LL cells
(7.5 × 104 viable cells per mouse in 0.3ml of DMEM). At day 21,
animals were sacrificed and surface lung nodules were counted, as
described above. Mice were vaccinated with racotumomab-alum
at 50 or 200μg/dose, receiving 2 doses before (days −14 and −7)
and the third after (day +7) tumor cell inoculation.
STATISTICAL ANALYSIS
Statistical analyses were carried out using GraphPad Prism ver-
sion 3.0 (GraphPad Software, La Jolla, CA, USA).
RESULTS
PROTECTION AGAINST SPONTANEOUS LUNG TUMOR FORMATION BY
IMMUNIZATION WITH RACOTUMOMAB-ALUM
We first studied antitumor protection by the anti-idiotype mAb
racotumomab against the formation of lung nodules. Tumors
were induced in the flank of themice by subcutaneous injection of
3LL cells and lung lesions were formed by spontaneous metastatic
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spread. As shown in Figure 1A, growth of subcutaneous primary
tumors was not affected by vaccination with biweekly s.c. doses of
50μg of racotumomab-alum beginning at the day of tumor chal-
lenge. On the other hand, immunization significantly reduced
the formation of lung tumor nodules (Figure 1B), indicating
an increased NeuGcGM3 antigen expression in spontaneous
metastatic lesions in comparison to the primary tumor, as pre-
viously reported (Labrada et al., 2010). Most experiments were
performed using racotumomab produced in mouse ascites fluid.
Similar antitumor activity was found using a vaccine formulation
containing a bioreactor-obtained mAb within a dose range from
50 to 200μg per dose, with a reduction of about 40–50% in lung
nodule formation (data not shown).
COMBINATION OF ANTI-IDIOTYPE IMMUNIZATION WITH STANDARD
CHEMOTHERAPY
We then explored the antitumor response induced by
racotumomab-alum in combination or not with chemother-
apy. As racotumomab, pemetrexed had no significant effects
on subcutaneous 3LL primary tumors. Immunization with
FIGURE 1 | Antitumor protection against spontaneous lung nodule
formation by immunization with racotumomab-alum. Mice were
inoculated subcutaneously with 3LL cells and immunized with
racotumomab-alum at a dose of 50μg, as described in “Materials and
Methods.” (A) Subcutaneous primary tumor growth. Data represent mean
± SEM. No significant effects were detected between control and treated
animals. (B) Spontaneous lung tumor nodules. Immunization significantly
reduced the number of lung nodules compared to control. Data points
represent individual mice and horizontal lines indicate the median values.
Data were pooled from two independent experiments with similar results.
∗p = 0.0377 (unpaired t-test with Welch’s correction).
biweekly doses of the vaccine exerted a comparable effect on
spontaneous lung tumor formation to that of weekly i.p. cycles of
pemetrexed at a dose of 100mg/kg (Figure 2). Combination of
racotumomab-alumwith pemetrexed was highly effective against
lung nodules (see also Figure 2), although no significant syner-
gistic effect was observed as compared to each treatment alone
in the present experimental conditions. No antitumor effects
were observed with taxane-based chemotherapy using weekly
docetaxel at 20mg/kg (data not shown). In all cases, chemo-
immunotherapy protocols with pemetrexed were well-tolerated,
not affecting body weight gain, food and water consumption or
inducing other signs of overt toxicity.
ASSOCIATION OF NeuGc EXPRESSION WITH HIGHLY AGGRESSIVE
EXPERIMENTAL LUNG TUMOR FORMATION
We asked whether antitumor activity of ractumomab was truly
associated with expression of NeuGc-containing gangliosides in
tumor cells in the present mouse lung-cancer model. We estab-
lished a highly aggressive experimental disease by intravenous
lung colonization by 3LL cells. Lung lesions progressed rapidly
and control animals died about 25 days after challenge. In this
experimental condition, preliminary experiments demonstrated
no antitumor effects of racotumomab-alum, even starting immu-
nization before tumor cell challenge. We hypothesized that during
the rapid disease progression, tumor cells are not able to incorpo-
rate enough NeuGc from lung tissue, and immunization is not
effective. Thus, we decided to perform an ex vivo preincubation
of 3LL cells with purified NeuGc, following a method known to
induce expression of NeuGc gangliosides in the cell membrane
(Gabri et al., 2009). To confirm antigen expression, cells were ana-
lyzed by flow cytometry with a specific anti-NeuGcGM3 antibody.
FIGURE 2 | Effects of racotumomab-alum immunization and
chemotherapy on spontaneous lung nodule formation.Mice were
inoculated subcutaneously with 3LL cells, and then immunized with
racotumomab-alum (raco-alum) at 50μg/dose and/or administered with
pemetrexed (100mg/kg), as described in “Materials and Methods.” Data
were pooled from two independent experiments with similar results.
Results are shown as mean ± SEM. ∗p < 0.05, control versus raco-alum or
versus pemetrexed; ∗∗p < 0.01, control versus raco-alum plus pemetrexed
(ANOVA followed by Bonferroni’s multiple comparison test).
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FIGURE 3 | Effect of exogenous incorporation of NeuGc on
experimental lung tumor formation. 3LL cells were preincubated in vitro
with purified NeuGc and then injected intravenously in mice, as described
in “Materials and Methods.” (A) Flow cytometryc analysis of 3LL cells after
preincubation with purified NeuGc, resulting in an increase of NeuGcGM3
ganglioside in cell membrane, as detected by the specific 14F7mAb. White
and gray curves present results from control and NeuGc-preincubated cells,
respectively. (B) Total lung tumor nodules experimentally formed by control
or NeuGc-preincubated 3LL cells. (C) Experimental formation of lung
macronodules (>2mm in diameter) by control or NeuGc-preincubated 3LL
cells. Lung lesions are shown as mean ± SEM. ∗∗p < 0.01 (unpaired t-test
with Welch’s correction).
While a marked staining was detected in NeuGc-preincubated
cells, control 3LL cultured cells were almost negative (Figure 3A).
We also checked the in vitro sensitivity of NeuGc-preincubated
tumor cells to chemotherapy. The IC50 for pemetrexed after a
3-day exposure of rapidly-growing 3LL cells was about 200 nM
(193 ± 6 nM). A similar IC50 value was found in 3LL cells prein-
cubated with NeuGc (192 ± 31 nM), suggesting no direct effects
of target antigen expression on chemotherapy effectiveness.
Preincubation with NeuGc significantly increased the for-
mation of experimental lung tumor nodules, particularly the
FIGURE 4 | Antitumor activity of racotumomab-alum vaccination in
highly aggressive, NeuGcGM3-positive experimental lung tumors.
Mice were vaccinated with racotumomab-alum (raco-alum) and then
injected intravenously with control or NeuGc-preincubated 3LL cells, as
described in “Materials and Methods.” (A) Total lung tumor nodules.
(B) Lung macronodules (>2mm in diameter). Lung lesions are shown as
mean ± SEM. ∗p < 0.05, control versus raco-alum at 200μg/dose (ANOVA
followed by Bonferroni’s multiple comparison test).
macronodules of more than 2mm in diameter (Figures 3B,C). A
significant antitumor activity was obtained for macronodules by
vaccination with racotumomab-alum at 200μg per dose in this
highly aggressive, NeuGcGM3-positive lung disease (Figure 4).
ANTIGEN-SPECIFIC IMMUNE RESPONSE IN MICE VACCINATED WITH
RACOTUMOMAB-ALUM
Finally, we addressed the NeuGc-specific immune response in
mice bearing subcutaneous 3LL tumors. Animals were chal-
lenged with 3LL cells preincubated or not with purified NeuGc,
and tumors were allowed to progress. Then, the sera were ana-
lyzed by flow cytometry using the X63 murine cell line, in
which NeuGcGM3 is the major ganglioside expressed on the cell
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FIGURE 5 | NeuGc-specific humoral response elicited by
racotumomab-alum vaccination. Mice were challenged subcutaneously
with 3LL cells preincubated or not with purified NeuGc, and immunized
with racotumomab-alum (raco-alum) at 50μg/dose, as described in
“Materials and Methods.” After tumor growth, pooled sera from the
different groups were obtained and analyzed by flow cytometry against X63
cells expressing NeuGcGM3 ganglioside. (A) Flow cytometric analysis.
(B) Percent of recognized X63 cells. Data from healthy untreated mice
(black line), mice bearing control 3LL tumors (dotted line), mice bearing
NeuGc-enriched 3LL tumors (gray line), and mice bearing NeuGc-enriched
3LL tumors and immunized with raco-alum (filled bar).
membranes (Hernandez et al., 2008). As shown in Figure 5, no
reactivity was observed either in mice bearing NeuGc-enriched
or control 3LL tumors. On the contrary, the sera from tumor-
bearing animals that were immunized with racotumomab-alum
reacted brightly against X63 cells expressing NeuGcGM3 (see also
Figure 5).
DISCUSSION
The development of cancer vaccines, aimed to enhance the
immune response against a tumor, is a promising area of research.
Preclinical studies would support the development of vaccination
strategies with enhanced clinical efficacy (Palena et al., 2006). In
this regard, mouse models are excellent tools to test efficacy of
novel therapies and to understand the biological mechanisms that
govern the generation of an effective antitumor response. One of
the main challenges in developing mAb-based cancer therapies
directed to glycolipids is to find attractive targets, with spe-
cific expression in tumors and a documented role during tumor
progression. This is not easy to demonstrate experimentally in
murine models, since mouse tumors often do not express sim-
ilar glycolipids as human tumors do. Besides, human xenograft
tumors can grow in immunodeficient athymic mice which are
precluded for active immunotherapy studies.
In the present work, we obtained evidence suggesting that
exogenous incorporation of NeuGc promotes the metastatic
potential of 3LL lung cancer cells and that antitumor activity of
the anti-idiotype mAb racotumomab is associated to NeuGcGM3
expression in tumor nodules. Previously, we reported that cul-
tured mouse melanoma and mammary cancer cells are able to
process and incorporate NeuGc from different sources such as
fetal bovine serum, NeuGc-rich mucins or purified NeuGc, thus
promoting the formation of blood-borne metastases (Gabri et al.,
2009). NeuGc increased the adhesive properties of tumor cells and
seemed to be involved in tumor nesting at distant sites. Similarly,
the 3LL Lewis lung carcinoma model was consistent with an
increased expression of NeuGcGM3 from subcutaneous primary
tumors to spontaneous metastatic lung nodules (Labrada et al.,
2010).
In most mammals, the synthesis of NeuGc is catalyzed by
the cytidine monophospho-N-acetylneuraminic acid hydroxy-
lase. However, the enzyme is inactivated due to a frameshift
mutation in human beings (Irie et al., 1998), and also absent in
both human and many mouse cancer cell lines (Segatori et al.,
2012). Tumors seem to incorporate NeuGc from dietary sources
or the tissue microenvironment. It is known that resistant can-
cer cells could overexpress NeuGc-containing gangliosides under
hypoxic conditions by inducing the sialic acid transporter sialin
(Yin et al., 2006).
The ganglioside NeuGcGM3 has been described in several
human neoplasms, including NSCLC (van Cruijsen et al., 2009;
Blanco et al., 2012), but is usually not detected in healthy
human tissues and fluids (Tangvoranuntakul et al., 2003). This
fact defines NeuGcGM3 as an interesting neoantigen target
for immunotherapy (Fernandez et al., 2010). Assessment of
NeuGcGM3 expression in about 200 samples of NSCLC by
tissue microarray immunohistochemistry demonstrated a wide
expression in more than 90% of cases. Moreover, based on the
expression of CD83, which is a marker of mature dendritic cells,
NeuGcGM3 appeared to be involved in tumor-induced dendritic
cell suppression (van Cruijsen et al., 2009).
A biweekly immunization protocol with racotumomab-alum
was highly effective against 3LL lung tumor nodules, either
alone or in combination with chemotherapy cycles of peme-
trexed (Alimta™). As described previously, the therapeutic effect
of racotumomab-alum was associated to an increase of CD4+
and CD8+ T cell infiltration, a reduced angiogenesis and tumor
cell apoptosis in lung nodules, although measurable antibodies
were not detected against purified NeuGcGM3 by ELISA assay
in C57BL/6 mice (Diaz et al., 2009). Here, we demonstrated that
sera from tumor-bearing mice immunized with racotumomab-
alum can recognize X63 cells overexpressing NeuGcGM3. It is
important to note that sera from non-vaccinated animals bearing
3LL tumors (either with or without NeuGc enrichment) were
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unable to react with X63 cells indicating that immune response
to antigen-positive cells is not elicited by tumor progression
itself.
In human NSCLC patients vaccinated with racotumomab, it
was suggested a correlation between the induction of IgG or IgM
against NeuGcGM3 and longer survival (Hernandez et al., 2008).
Anti-NeuGcGM3 specific antibodies were capable of recognizing
and killing tumor cells expressing the antigen, by a mechanism
resemble the oncotic necrosis (Hernandez et al., 2011).
To our knowledge, this is the first preclinical report
demonstrating the feasibility of the combination of the anti-
idiotype mAb racotumomab with chemotherapeutic drugs such
as pemetrexed, and thus providing a rationale for chemo-
immunotherapy combinations in NSCLC. Our experimental
data also contribute to reinforce the biological significance of
NeuGcGM3 ganglioside as a target for cancer immunotherapy.
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